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ABSTRACT
Introduction: Answering the demands of an
increasingly young and active patient population, recent
developments in total hip arthroplasty (THA) have shifted
towards minimising tissue damage. The Collum Femoris
Preserving (CFP) stem was developed to preserve the
trochanteric region of the femur, which potentially
preserves the insertion of the gluteus musculature. This
might accelerate early postoperative rehabilitation and
improve functional outcome. Currently the functional
results of the CFP stem have not been compared with
conventional straight stems in a randomised controlled
trial (RCT). The primary purpose of this trial is to
compare the functional result of CFP stem THA with
conventional uncemented straight stem THA, measured
by the Dutch Hip disability and Osteoarthritis Outcome
Score (HOOS) at 3-month follow-up.
Methods: A prospective blinded multicentre RCT will be
performed. We aim to recruit 150 patients. The patients
will be randomly allocated to a THA with a straight or a
curved stem. All patients, research assistants, clinical
assessors and investigators will be blinded for the type of
prosthesis for 5 years. Clinical assessments and
roentgenograms will be taken preoperative, at 6 weeks
after surgery, at 1, 2, 3, 4 and 5 years after surgery.
Patient reported outcome measures (PROMs) will be
obtained at the same follow-up moments. In addition, the
PROMs will also be sent to the patients at 3 and
6 months after surgery. The HOOS at 3-month follow-up
will be our primary outcome.
Ethics and dissemination: This trial will be performed
in accordance with the Declaration of Helsinki. A local
ethics committee has approved this trial. Written
informed consent will be obtained from all participating
patients. All serious adverse events will be reported to the
ethics committee.
Results: Results will be submitted for publication to an
orthopaedics related journal.
Trial registration number: NTR1560.
INTRODUCTION
For years, developments in total hip arthro-
plasty (THA) have focused mainly on improv-
ing implant survival, resulting in long-term
survival rates of more than 90% for unce-
mented as well as cemented stems.1
There is a recent increase in uncemented
hip replacements, especially in young and
more active patients. Uncemented stems are
currently the preferred implant of choice for
these patients, providing that there is a good
bone quality.2 The Zweymuller stem is a com-
monly used uncemented straight stem and
studies have shown excellent 10-year survival
rates of 90–100%.3–6 Weissinger et al7 have
shown a reoperation rate of 6.8% after
20 years. Furthermore, stability of the
implant was not affected by any proximal
osteolysis.8 9 The proximal anchorage of this
stem requires the use of a box chisel cutting
a slot in the trochanteric fossa near the inser-
tion of both the gluteus medius and the piri-
formis tendon to obtain entry in neutral
Strengths and limitations of this study
▪ A good methodological quality, which reduces
the risk of bias.
▪ A multicentre randomised controlled trial.
▪ Maximally blinded (patients, clinical assessors,
investigators and data analysts are blinded for
the type of implant).
▪ A research assistant is hired for this study, to
ensure that there will be complete data and a
maximal follow-up.
▪ Sealed envelopes instead of a digital system are
used for the randomisation.
van Beers LWAH, et al. BMJ Open 2016;6:e010472. doi:10.1136/bmjopen-2015-010472 1
Open Access Protocol
group.bmj.com on May 30, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
alignment. A previous cadaver study by van Oldenrijk
et al10 demonstrated a median gluteus medius midsub-
stance surface area damage of 22% (minimum 6,
maximum 40%) after Zweymuller stem placement using
a lateral transgluteus approach. Moreover, the external
rotators were found to be unintentionally transected in
one of ﬁve hips using this approach. Damage to the
insertion of the gluteus musculature is an important
cause of postoperative pain at the greater trochanter
and reduced abductor strength, resulting in limping and
a positive Trendelenburg gait.11–13
In the young and active patient population, recent
developments have, therefore, shifted towards minimis-
ing tissue damage, thereby retaining normal bone physi-
ology without compromising implant stability. This
resulted in the modiﬁcation of surgical techniques and
the development of innovative bone and soft tissue-
preserving implants, such as short stem hip arthroplasty.
The aim of these developments was to accelerate early
postoperative rehabilitation, improve functional
outcome and preserve bone stock for future revisions.14
Short stem THA aims to combine well-established
anchoring principles with bone preservation. Pipino and
Calderale 15 introduced the Biodynamic stem. This stem
preserves the collum femoris, thereby preserving prox-
imal bone stock for any future revisions. Furthermore, it
preserves the trochanteric region of the femur. As such,
it preserves the gluteal insertions on the greater trochan-
ter, which may be beneﬁcial as compared to a conven-
tional stem, as this may potentially accelerate early
postoperative rehabilitation. The Biodynamic stem,
showing good medium and long-term survival rates,16 17
was later modiﬁed into the collum femoris preserving
(CFP) stem (Waldemar Link, Germany). A case series
(mean follow-up of 5.1 years) demonstrated excellent
integration and survivorship at medium follow-up (mean
5.1 years), with a revision rate of 0.21 per year.18–28
Clinical follow-up also showed good functional recovery
and DEXA analysis of 10 patients showed minimal peri-
prosthetic bone loss.16 18 Two-year follow-up migration
assessment using radiostereometry showed low migra-
tion, suggesting a favourable long-term outcome.26 29
The quality of this currently available evidence is low,
and no study has compared this stem with a conven-
tional stem, so only a weak recommendation can be pro-
vided for clinical usage of these short stem designs.30
Stronger evidence is necessary, preferably prospective
multicentre randomised trials, before widespread use
can be recommended.30
Since the potential beneﬁts of the CFP stem have not
yet been compared with conventional straight stems in a
randomised controlled trial (RCT), the potential add-
itional beneﬁt in terms of short-term rehabilitation
remain to be determined. We aim to compare the early
(3 month) and medium (up to 5 years) term functional
result of a CFP stem THA to conventional straight stem
THA. The primary purpose of this trial is to compare
the functional result of CFP stem THA with conventional
uncemented straight stem THA, measured by the Dutch
version of the Hip disability and Osteoarthritis Outcome
Score (HOOS)31 at 3-month follow-up.
The secondary objective will be an evaluation of sec-
ondary outcomes discussed in detail below. Since the
CFP stem may require less dissection of the gluteal mus-
culature off the greater trochanter, we expect to ﬁnd a
better short-term functional result after CFP stem THA
compared with conventional straight stem THA, as
reﬂected in higher HOOS.
METHODS
Trial design
A prospective blinded randomised controlled multicen-
tre trial with parallel groups will be performed at Onze
Lieve Vrouwe Gasthuis (OLVG) in Amsterdam and at
Ikazia hospital in Rotterdam, both in The Netherlands.
A total of 100 patients from OLVG and 50 patients from
Ikazia will be recruited. Three orthopaedic surgeons
from OLVG, and two orthopaedic surgeons from Ikazia,
participate in this trial. The allocation ratio between the
two interventions will be 1:1, and a superiority design
will be used. This trial is registered at the Dutch Trial
Registry (Nederlands Trial Register, http://www.
trialregister.nl) on 25 November 2008, ﬁle number
NTR1560.
Participants
We will include patients between 18 and 70 years with
osteoarthritis of the hip, who are not responding to con-
servative therapy, who meet the clinical criteria to
undergo a cementless THA, and are willing to sign
written informed consent. Consecutive patients from the
waiting list for a total hip replacement will be
approached for participating in this trial if they meet the
inclusion criteria. Patients will be excluded when they:
are not able to ﬁll out the Dutch questionnaires; have
morbid obesity with a body mass index of more than
40 mm Hg; have an altered anatomy resulting in impossi-
bility for one of the procedures; have a life expectancy
of <5 years; have had a lower extremity amputation; have
a known alcohol or drugs abuse; have an active malig-
nant disease or current cytostatic treatment; are partici-
pating in another clinical trial; have contralateral hip
pain; have had a previous hip arthroplasty (ipsilateral or
contralateral), or when they have avascular head necro-
sis due to sickle cell anaemia.
All orthopaedic surgeons will be informed about this
trial through presentations, posters and newsletters. The
orthopaedic surgeons will screen all patients in the out-
patient clinic for eligibility, and they will inform eligible
patients about the trial. A researcher will contact
the patient by phone to resolve any questions. When the
patient agrees to participate in this trial, informed
consent has to be signed by both the orthopaedic
surgeon or research assistant and the patient. After
enrolment in this trial, patients will be assigned to a
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study identiﬁcation number. Only the study identiﬁca-
tion number will be used on data forms and in the data-
bases. The encryption between the study identiﬁcation
number and the personal information will only be
accessible for the research coordinator of this trial.
Randomisation and blinding
After signing the informed consent, the patient will be
randomly allocated to THA with a straight stem or a
curved stem. Stratiﬁed block randomisation will be used
as allocation method. Blocks consist of 10 consecutive
surgical procedures. At the end of each block an equal
distribution of patients between the two groups will have
been reached. Patient allocation will be stratiﬁed to
surgeon, resulting in an equal distribution of surgical
expertise and technique variation in each group.
Randomisation will not be performed until the moment
of surgery. The surgeon will, therefore, perform pre-
operative templating for both stems, and both stems and
their instrumentation trays will be available in the
surgery room. Since a digital randomisation system
proved to be unsuccessful in our hospital due to tech-
nical difﬁculties, randomisation will be performed using
envelopes. We will use randomisation envelopes that are
sealed, sequentially numbered, opaque and blinded. An
independent investigator will make these randomisation
envelopes available to the surgeon in the operating
room, after the patient is under anaesthesia, and just
before incision. Both types of implants are ready to use
in the operating room. All patients, researchers, clinical
assessors and investigators will be blinded for the type of
prosthesis for the total duration of the follow-up: 5 years.
A pop-up message will be attached to the patient records
in the electronically maintained hospital information
system. This pop-up message is a reminder that the
patient and clinical assessors are blinded, and therefore,
the roentgenograms should not be shown. Only the
orthopaedic surgeon will verify the roentgenograms, so
in case there are any problems, they can be intervened.
Data will be processed and analysed by blinded investiga-
tors. After ﬁnalising data analyses the blinding will be
broken for publication purposes.
The number of deblinded patients will be recorded
and presented in ﬁnal reports.
Interventions
All participating surgeons should have gained experi-
ence with both implants. At least ﬁve procedures for
both implants should have been performed prior to par-
ticipating in the trial. The learning curve for the CFP
stem is assessed in an earlier study,28 32 and an accept-
able level of proﬁciency is assumed after performing ﬁve
procedures.
A lateral transgluteal approach in lateral decubitus
position is used in all patients.
The same rehabilitation protocol will be used for both
groups. Postoperatively, patients are allowed to fully
weight bear with the use of crutches from the ﬁrst
postoperative day, continuing crutches if necessary
during the ﬁrst 6 weeks.
Straight stemmed THA
Patients randomised into the straight stem group will
undergo surgery for THA where a straight, cementless,
Alloclassic stem (Zimmer, Warsaw, Indiana, USA) will be
used. This stem is inserted parallel to the longitudinal
axis of the femur.
Curved stemmed THA
Patients randomised into the curved stem group will
undergo surgery for THA where a curved, cementless,
CFP stem (Waldemar Link, Hamburg, Germany) will be
used. This stem follows the curvature of the remaining
femoral neck. Two curvatures are available: A for coxa
valga and norma, and B for coxa vara. The curvature
will be assessed preoperatively by templating the hip.
Cup
A Trabeculae Oriented Pattern (TOP) cementless hemi-
spheric cup (Waldemar Link, Hamburg, Germany) with
a polyethylene liner will be used in both groups. The
TOP cup has a biequatorial dissociation with a medial-
caudal recess to allow a wider range of motion and an
elevated cranial rim to reduce the risk of dislocation.17
A follow-up study of 301 TOP cups showed no detach-
ment, migration or osteolysis after 7 years.18 All implants
are positioned without the use of navigation.
Head
In both groups a 32 or 28 mm ceramic head is used.
Outcome measures
Primary outcome
The Dutch version of HOOS31 at 3 months post-
operative, will be our primary outcome. The HOOS is a
patient-reported outcome measure (PROM) that consists
of ﬁve subscales; pain, other symptoms, function in daily
living, function in sport and recreation and hip-related
quality of life. Standardised answering options are given
for each question (ﬁve Likert boxes) ranging from 0 to
4. A normalised score (100 indicating no symptoms and
0 indicating extreme symptoms) is calculated for each
subscale.
Secondary outcomes
Secondary outcomes will be the amount of reoperations
due to implant-related complications, for example,
bleeding or vascular damage, neurogenic damage, frac-
tures, dislocation, infection, loosening, deep venous
thrombosis. Other secondary outcomes are pain in the
ipsilateral and contralateral hip, knees and back, mea-
sured by a numeric rating scale (NRS), abductor
strength measured by the Trendelenburg test,33 walking
ability measured by the Timed Up and Go (TUG)
test,34 35 physical functioning measured by the Harris
Hip Score (HHS),36 general health measured by the
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Short-Form 12 item (SF-12) questionnaire,37 quality of
life by the EuroQol 5 Dimension (EQ-5D) question-
naire,38 and position of the prosthesis. The position of
the prosthesis will be measured on weight-bearing
anteroposterior pelvis with the patient’s feet facing
forward and hip faux proﬁle roentgenograms.
Preoperatively an X-ray will be taken which includes a
ball of known diameter to enable calibration.
Postoperatively X-rays are taken at day 1, 6 weeks, and
annually up to 5 years after surgery. An assessor who is
not involved with the surgical procedures will perform
all measurements.
The clinical assessments, containing the range of
motion of the hip, the Trendelenburg test, the TUG
test, measuring leg length discrepancy and asking for
the occurrence of any complications, will be performed
at baseline (within 1 week prior to surgery), at 6 weeks
after surgery, at 1, 2, 3, 4 and 5 years after surgery. A
trained researcher will perform all clinical tests.
Roentgenograms will be taken at the same time points.
The PROMs, containing the HOOS, NRS, HHS, SF-12
and EQ-5D, can be ﬁlled out using either pen and
paper or web-based forms. The PROMs will be sent to
the patient’s home address (including prestamped
return envelopes) or e-mail address. Patients are asked
to ﬁll out the PROMs at the same follow-up moments as
the clinical assessments. In addition, the PROMs will
also be sent to the patients 3 and 6 months after surgery.
All follow-up moments are presented schematically in
table 1. Every patient will receive a reminding card con-
taining the date of surgery and the subsequent months/
years of clinical follow-up. For every follow-up visit,
patients will be contacted by phone to make an appoint-
ment. Patients who have not responded to the PROMs,
are contacted by phone as a reminder. Patients will be
kept informed about the trial by sending them newslet-
ters, approximately twice a year. In addition, every
patient chart has a note for doctors, that in case of any
complication the research coordinator should be
contacted.
Sample size
Sample size calculation is based on the HOOS pain sub-
scale, to detect a difference between the two groups at
3 months postoperative. De Groot et al31 found a mean
HOOS pain score of 65.4 points with an SD of 14.3 in
patients 9.5 months after THA. We consider a 10%
difference in outcome clinically relevant, resulting in a
seven-point difference.39 Based on these assumptions,
setting α at 0.05 and the power level at 80%, a sample
size of 67 patients in each group is required to detect a
statistically signiﬁcant difference.
We expect a maximum drop-out rate of 10%, resulting
in a total of 150 patients (75 patients in the curved stem
group and 75 patients in the straight stem group).
We expect to recruit the 150 patients within a period
of 2 years.
Statistical analyses
To investigate the effect of both implants, we will use
generalised estimating equations (GEE) for longitudinal
analysis in SPSS. All patients who withdraw from the trial
after surgery, and patients who undergo a revision
surgery, will be included in an intention-to-treat analysis.
Both intention-to-treat analysis and per-protocol analysis
will be performed. This method takes into account the
dependency of observations within a patient, and the
fact that not all patients may be assessed at each time
point (missing data).
Primary analyses
In the primary GEE model, the outcome variable
studied (eg, physical function on the HOOS) will be
analysed as a dependent variable, using implant alloca-
tion (1, CFP; 0, Zweymuller) and time as key independ-
ent variables. The primary endpoint of the study is on
the effect at 3 months, but all time moments will be ana-
lysed in the same GEE model.
Secondary analyses
In the secondary GEE model, the outcome variables
studied (eg, physical function on the HHS, general
health on the SF12, quality of life on the EQ5D, walking
ability on the TUG, pain on the NRS, hip range of
motion, abductor strength on the Trendelenburg test,
position of the prosthesis and leg length discrepancy on
the roentgenograms, satisfaction) will be analysed in a
similar way. To evaluate whether the two implant groups
differed in change over time, the interaction term of
group and time (group×time) will be assessed. Time will
be included as a dummy variable (reference=baseline
T0), and seven interaction terms will be analysed (T1 6
weeks×group, T2 3 months×group; T3 6 months×group;
T4 1 year×group, T5 2 years×group, T6 3 years×group,
Table 1 Follow-up moments
Preoperative Postoperative
Baseline 6 Weeks 3 Months 6 Months 1 Year 2 Years 3 Years 4 Years 5 Years
PROMs X X X X X X X X X
Clinical tests X X X X X X X
Roentgenograms X X X X X X X
PROMs, patient-reported outcome measures.
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T7 4 years×group, T8 5 years×group). All models will be
corrected for centre of inclusion and surgeon. In add-
itional analysis, we will investigate the possible confound-
ing effect (deﬁned as more than 10% change in the
parameter estimate for group×time) of several variables
(body mass index, gender, ASA-classiﬁcation, comorbid-
ity, mental health, other joint pain). At the following
time points following the surgery (T4, T5, T6, T7 and
T8), we will describe the incidence of reoperations
(both implant groups) using descriptives. For all analysis,
a two-tailed value of p<0.05 is considered to be
signiﬁcant.
Data storage
Data will be entered into a digital database (SPSS), and
after the data entry, paper data collection forms will be
stored in an archive. Both paper forms and digital data-
bases will be accessible only to the research coordinator.
Steering and data monitoring committee
No ofﬁcial steering committee has been appointed for
this study. The following representatives from the partici-
pating organisations are involved in the project oversight
and control: RWP (principal investigator and sponsor),
JvO, CHG, BBAMN, VABS and LWAHvB. All study-
related problems or (serious) adverse events will be dis-
cussed with the principal investigator RWP, and research-
ers VABS, LWAHvB and JvO. SAEs will be ofﬁcially
reported to the ethical committee. The ethical commit-
tee judges whether the safety of the patients is jeopar-
dised, and whether the trial can be continued or not.
There is no ofﬁcial data monitoring committee. Data
entry will be performed by one of the researchers
(LWAHvB). All entered data will be checked and
cleaned (LWAHvB and VABS) according to the quality
handbook of the emgo+institute for health and care
research (http://www.emgo.nl/kc). In addition, a
random sample of 20% of the data will be re-entered by
another researcher ( JvO) to check for inconsistencies. A
third researcher (VABS) will be involved with the data
processing and analysis, which will be performed
without knowledge of the allocation key. All data analysis
(VABS) will be discussed with the researchers (RWP, JvO
and LWAHvB) prior to deblinding, before ﬁnal presenta-
tion of the results.
Interim analysis will be performed after 2 years. Data
analysts and researchers are still blinded to the type of
prosthesis at that time point. Results of the interim ana-
lysis will be discussed with the researchers.
Ethics and dissemination
This trial will be performed in accordance with the
Declaration of Helsinki. All substantial amendments to
the protocol will be notiﬁed to the ethics committee
and to the competent authority. Non-substantial amend-
ments will not be notiﬁed to the accredited METC and
the competent authority, but will be recorded and ﬁled
by the sponsor. Written informed consent will be
obtained from all participating patients. The research
coordinator will report all serious adverse events within
24 h after noticing any, using the online submission
system of the ethics committee. The ethical committee
judges whether the safety of the patients is jeopardised,
and whether the trial can be continued or not. Results
will be submitted for publication to an orthopaedics-
related journal.
Protecting against sources of bias
Selection bias
In this trial, the risk of selection bias is reduced by
approaching all consecutive eligible patients.
Furthermore, randomisation will not be performed
until the moment of surgery. This will prevent selecting
patients for a speciﬁc type of prosthesis.
Performance bias (blinding)
Unblinded patients allocated to an intervention which
they do not prefer, may feel resentful. This may lead to
performance bias.40 41 In this trial, all patients will be
blinded to the type of prosthesis, reducing the risk of
performance bias.
Performance bias (surgeon expertise)
Requiring a minimum number of procedures prior to
initiating the trial reduces the risk of performance bias.
Detection bias
The clinical assessors who will perform the clinical tests
will be blinded, to reduce the risk of detection bias.
Attrition bias
To reduce attrition bias, a blinded research assistant is
the direct contact person for all trial patients. Efforts are
undertaken to minimise the amount of patient drop-out
or lost to follow-up. Moreover, all PROMs and clinical
assessment data is veriﬁed to prevent incomplete data.
Publication bias
By publishing this protocol, we would like to prevent
publication bias. Results of this trial will be submitted
for publication in a peer-reviewed journal.
Minimising cointerventions and contamination
Crossover between intervention groups can occur, for
instance, when a revision surgery will be performed and
another type of stem will be implanted. All patients will
be analysed in the group to which they were allocated
following the intention-to-treat analysis. Additionally, we
can perform per-protocol analysis.
DISCUSSION
Authors of surgical RCTs often fail to report measures to
prevent bias.42–46 Several reviews of RCTs in orthopaedic
surgery have studied the reporting of bias prevention.
They found that this is often not well reported. Blinding
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of outcome assessors, concealment of allocation, and
intention-to-treat analysis are types of bias preventions
that are often not reported.40 41 47 In this trial, extensive
measures will be taken to reduce the risk of bias. It will
be a challenge to keep all involved persons, patients as
well as research staff, blinded for 5 years. These strenu-
ous measures to reduce the risk of bias may serve as a
model for future implant-related orthopaedic RCTs.
This trial will be the ﬁrst RCT that compares the early
and medium-term functional results of the CFP stem
THA with conventional straight stem (Zweymuller)
THA. Herewith, this trial can contribute to the clinical
evidence around short stem THA.
At ﬁrst sight, 3 months follow-up might not be the
most clinically relevant time point to evaluate. This time
point was chosen as it best reﬂects the timing to evaluate
the theoretical advantage of the CFP stem as compared
with the Zweymuller stem; for example, that the gluteal
musculature might be less damaged. This preserving of
gluteal musculature might be beneﬁcial for the acceler-
ation of rehabilitation/improved physical functioning of
the patients, in particular, in the ﬁrst months after
surgery. The intention of this trial is to evaluate whether
the theoretical advantages of the CFP stem do really
result in better physical functioning, compared to the
Zweymuller. For that reason, we choose 3-month
follow-up as our primary end point. Naturally, mid-term
and long-term results of prosthetic stems are valuable.
For that reason, we will follow all patients up to 5 years
after surgery.
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